Recent investigations have centered on the intersection of GLP|glucose-dependent insulinotropic polypeptide|GCGR agonist therapies and dopamine neurotransmission. While GIP agonists are widely employed for managing type 2 diabetes, their unexpected effects on reinforcement circuits, specifically